Key Highlights
- AOTI LSE:AOTI is shown 3.85% higher on 21 September 2026.
- The company remains in focus following progress towards potential US Medicare coverage for topical oxygen therapy.
- AOTI's TWO2 therapy is designed for patients with chronic wounds, including difficult-to-heal diabetic foot ulcers.
- First-half 2026 Revenue increased 10% to approximately US$35 million, while underlying revenue growth excluding Arizona Medicaid reached 18%.
- A public meeting relating to the proposed US coverage determination concluded with unanimous favourable support from commenters in August.
- AOTI is scheduled to report its interim results on 30 September 2026, making the upcoming results a key event for investors.
Why Is AOTI LSE:AOTI in Focus on 21 September 2026?
AOTI LSE:AOTI is attracting attention after rising 3.85% on 21 September 2026, with investors continuing to follow developments surrounding the company's TWO2 topical oxygen therapy platform and its potential expansion across the US healthcare market.
The company's Investment story has increasingly centred on the possibility of wider Medicare reimbursement for topical oxygen therapy. A proposed US coverage determination has already been issued for topical oxygen therapy in certain diabetic foot ulcer cases, creating a potentially significant change in the addressable market if the proposal progresses to a final determination.
At the same time, AOTI's operating performance has been improving, with first-half revenue growth and stronger underlying Demand providing another reason for Market Participants to monitor the company.
What Is Driving the Latest Interest in AOTI LSE:AOTI?
The key development is the proposed expansion of Medicare coverage for topical oxygen therapy.
The proposed coverage relates to Medicare beneficiaries with diabetic foot ulcers that have failed to heal following four consecutive weeks of optimised diabetic foot ulcer care. AOTI has described the potential coverage expansion as an important market-access milestone for its TWO2 therapy.
The proposal entered a public-comment process, and the virtual open public meeting held in August concluded with commenters unanimously supporting the proposed coverage language.
The eventual outcome remains important because broader Medicare reimbursement could increase access to AOTI's therapy among eligible US patients.
Could Medicare Coverage Become a Major Catalyst for LSE:AOTI?
Medicare coverage is one of the most closely watched developments surrounding AOTI.
The company has previously indicated that a final coverage determination could materially expand the US market opportunity for TWO2 therapy. The proposed determination covers topical oxygen therapy for qualifying diabetic foot ulcer patients, subject to the specified treatment criteria.
AOTI already has a commercial infrastructure across a large portion of the US, meaning any expansion in reimbursement could potentially be supported by its existing sales and treatment network.
However, the proposed determination is not the same as a final reimbursement decision. Investors are therefore watching the regulatory process and the company's subsequent commercial execution.
How Has AOTI LSE:AOTI Been Performing Financially?
AOTI's first-half 2026 trading update showed revenue of approximately US$35 million, representing a 10% year-on-year increase.
Underlying revenue growth excluding the discontinued Arizona Medicaid activity reached 18%, above the company's previous mid-teens full-year growth guidance.
Veterans Administration sales increased approximately 15%, while Medicaid revenue outside Arizona increased approximately 21% on an underlying basis. The company ended June with approximately US$13.8 million of cash and US$6.3 million of net debt.
These figures give investors an additional basis for assessing whether operational growth is continuing ahead of the potential Medicare opportunity.
Why Is TWO2 Therapy Important for AOTI?
TWO2 is AOTI's topical oxygen therapy platform and is central to the company's Business strategy.
The technology is designed to provide intermittent topical oxygen treatment for chronic wounds. The company has focused particularly on difficult-to-heal wounds and diabetic foot ulcers, where delayed healing can lead to prolonged treatment requirements and, in severe cases, amputation.
AOTI's previous clinical and real-world evidence has been an important part of its efforts to support broader adoption and reimbursement of the therapy.
The proposed Medicare coverage therefore represents more than a regulatory development: it could influence the potential number of eligible patients and the reimbursement environment in which TWO2 operates.
What Are Investors Watching Ahead of AOTI's September Results?
AOTI is scheduled to report its interim results on 30 September 2026.
The results could provide investors with updated information on revenue growth, cash generation, debt, Veterans Administration sales, Medicaid activity and the performance of the company's commercial operations.
Investors are also likely to focus on management's commentary regarding the proposed Medicare coverage determination and the expected timing of further developments.
The combination of financial results and reimbursement progress makes the end of September an important period for LSE:AOTI.
Why Has AOTI LSE:AOTI Been Volatile During September?
AOTI has experienced notable price movements during recent weeks. Historical market data shows several sizeable daily changes during September, including a 7.41% decline on 1 September and a 6.25% increase on 9 September.
This Volatility reflects the market's sensitivity to news surrounding AOTI's growth outlook, Medicare coverage prospects and its relatively small-cap healthcare profile.
The latest 3.85% gain on 21 September therefore comes within a broader period of active trading and changing expectations around the company's future market opportunity.
What Could Keep LSE:AOTI in Focus Going Forward?
Several developments could continue to influence investor attention.
The first is the progression of the proposed Medicare coverage determination. The second is AOTI's 30 September interim results, which should provide a more detailed update on first-half performance and the company's outlook.
Investors may also monitor the pace of TWO2 adoption, US Veterans Administration demand, Medicaid developments and the company's cash and Debt position.
The commercial impact of any eventual Medicare coverage expansion will also depend on patient eligibility, reimbursement implementation, healthcare-provider adoption and AOTI's ability to convert the broader addressable market into revenue.
What Does the 3.85% Rise Mean for AOTI LSE:AOTI?
AOTI LSE:AOTI is shown 3.85% higher on 21 September 2026, putting the healthcare stock among the notable market movers for the session.
The latest move comes while investors are monitoring several overlapping catalysts: progress towards broader Medicare coverage, continued TWO2 demand, improving first-half revenue and the approaching interim results.
The company's next major information point is its 30 September 2026 interim results, while the progression of the proposed Medicare coverage determination remains a key longer-term Factor for the potential expansion of TWO2 therapy in the US.






Please wait processing your request...